SGLT2 inhibitor is kidney protective, even if eGFR <30

Media formats available:

Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
- Aaron Wong, MD
Effect of SGLT2i on diuretic efficacy in acute heart failure
Effect of SGLT2i on diuretic efficacy in acute heart failure
ESC Congress 2023
Effect of SGLT2i on diuretic efficacy in acute heart failure

PACE-CME